Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics

This article has been updated

Abstract

Preclinical toxicology studies are performed prior to phase I trials with novel cancer therapeutics to identify a safe clinical starting dose and potential human toxicities. The primary aim of this study was to evaluate the ability of rodent-only toxicology studies to identify a safe phase I trial starting dose. In addition, the ability of murine studies to predict the quantitative and qualitative human toxicology of cancer therapeutics was studied. Data for 25 cancer drugs were collated for which the preclinical and clinical routes and schedules of administration were either the same (22/25), or closely matched. The maximum tolerated dose/dose lethal to 10% of mice (MTD/LD10) was identified for 24 drugs, and in patients the maximum administered dose (MAD) was associated with dose-limiting toxicity (DLT) in initial clinical trials with 20 compounds. In addition, for 13 agents, the toxicity of the drug at one-tenth the mouse MTD/LD10 was also investigated in rats, following repeated administration (20 doses). A phase I trial starting dose of one-tenth the mouse MTD/LD10 (mg m–2) was, or would have been, safe for all 25 compounds. With the exception of nausea and vomiting, which cannot be assessed in rodents, other common DLTs were accurately predicted by the murine studies (i.e. 7/7 haematological and 3/3 neurological DLTs). For two of the 13 drugs studied in rats, repeated administration of one-tenth the mouse MTD/LD10 was toxic, leading to a reduction in the phase I trial starting dose; however, one-tenth the mouse MTD/LD10 was subsequently tolerated in patients. For the 20 drugs where clinical DLT was reached, the median ratio of the human MAD to the mouse MTD/LD10 was 2.6 (range 0.2–16) and the median ratio of the clinical starting dose to the MAD was 35 (range 2.3–160). In contrast, in 13 subsequent phase I trials with 11 of the initial 25 drugs, the median ratio of the clinical starting dose to the MAD was 2.8 (range 1.6–56), emphasizing the value of early clinical data in rapidly defining the dose range for therapeutic studies. For all 25 drugs studied, rodent-only toxicology provided a safe and rapid means of identifying the phase I trial starting dose and predicting commonly encountered DLTs. This study has shown that the routine use of a non-rodent species in preclinical toxicology studies prior to initial clinical trials with cancer therapeutics is not necessary.

Change history

  • 16 November 2011

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

  1. Arbuck, SG (1996) Workshop on Phase I study design. Ann Oncol 7: 567–573.

    CAS  Article  Google Scholar 

  2. Betteridge, RF, Bosanquet, AG & Gilby, ED (1990) Pharmacokinetics of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZQ, NSC224070) during a Phase I clinical trial. Eur J Cancer 26: 107–112.

    CAS  Article  Google Scholar 

  3. Burtles, SS, Newell, DR, Henrar, REC & Connors, TA (1995) Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. Eur J Cancer 31A: 408–410.

    CAS  Article  Google Scholar 

  4. Carmichael, J, Cantwell, BMJ, Mannix, KA, Veale, D, Elford, HL, Blackie, R, Kerr, DJ, Kaye, SB & Harris, AL (1990) A Phase I and pharmacokinetic study of didox administered by 36 hour infusion. Br J Cancer 61: 447–450.

    CAS  Article  Google Scholar 

  5. Collins, JM, Zaharko, DS, Dedrick, RL & Chabner, BA (1986) Potential roles for preclinical pharmacology in Phase I clinical trials. Cancer Treat Rep 70: 73–80.

    CAS  PubMed  Google Scholar 

  6. Collins, JM, Grieshaber, CK & Chabner, BA (1990) Pharmacologically guided Phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 82: 1321–1326.

    CAS  Article  Google Scholar 

  7. Decoster, G, Stein, G & Holdener, EE (1990) Responses and toxic deaths in Phase I clinical trials. Ann Oncol 1: 175–181.

    CAS  Article  Google Scholar 

  8. DeGeorge, JJ, Ahn, C-H, Andrews, PA, Brower, ME, Giorgio, DW, Goheer, ME, Lee-Ham, DY, McGuinn, WD, Schmidt, W, Sun, CJ & Tripathi, SC (1998) Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol 41: 173–185.

    CAS  Article  Google Scholar 

  9. Dent, SF & Eisenhauer, EA (1996) Phase I trial design: are new methodologies being put into practise?. Ann Oncol 7: 561–566.

    CAS  Article  Google Scholar 

  10. EORTC Pharmacokinetics and Metabolism Group (1987) Pharmacokinetically guided dose escalation in Phase I clinical trials. Eur J Cancer 23: 1083–1087.

  11. Estey, E, Hoth, D, Simon, R, Marsoni, S, Leyland-Jones, B & Wittes, R (1986) Therapeutic response in Phase I trials of antineoplastic agents. Cancer Treat Rep 70: 1105–1115.

    CAS  PubMed  Google Scholar 

  12. Foster, BJ, Newell, DR, Graham, MA, Gumbrell, LA, Jenns, KE, Kaye, SB & Calvert, AH (1992) Phase I trial of the anthrapyrazole CI-941: prospective evaluation of pharmacologically guided dose-escalation. Eur J Cancer 28: 463–469.

    CAS  Article  Google Scholar 

  13. Foster, BJ, Newell, DR, Carmichael, J, Harris, AL, Gumbrell, LA, Jones, M, Gogard, PM & Calvert, AH (1993a) Preclinical, Phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277. Br J Cancer 67: 362–368.

    CAS  Article  Google Scholar 

  14. Foster, BJ, Newell, DR, Gumbrell, LA, Jenns, KE & Calvert, AH (1993b) Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion. Br J Cancer 67: 369–373.

    CAS  Article  Google Scholar 

  15. Freireich, EJ, Gehan, EA, Rall, DP, Schmidt, LH & Skipper, HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep 50: 219–244.

    CAS  PubMed  Google Scholar 

  16. Goldsmith, MA, Slavik, M & Carter, SK (1975) Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res 35: 1354–1364.

    CAS  PubMed  Google Scholar 

  17. Grieshaber, CK & Marsoni, S (1986) Relationship of preclinical toxicology to findings in early clinical trials. Cancer Treat Rep 70: 65–72.

    CAS  PubMed  Google Scholar 

  18. Homan, ER (1972) Quantitative relationships between toxic doses of antitumour chemotherapeutic agents in animals and man. Cancer Chemother Rep Part 3 3: 13–19.

    CAS  Google Scholar 

  19. Horwich, A, Holliday, SB, Deacon, JM & Peckham, MJ (1986) A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitizer RSU-1069. Br J Radiol 59: 1238–1240.

    CAS  Article  Google Scholar 

  20. Jayson, GC, Crowther, D, Prendiville, J, McGown, AT, Scheid, C, Stern, P, Young, R, Brenchley, P, Chang, J, Owens, S & Pettit, GR (1995) A Phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 72: 461–468.

    CAS  Article  Google Scholar 

  21. Jodrell, DI, Bowman, A, Stewart, M, Dunlop, N, French, R, MacLellan, A, Cummings, J & Smyth, JF (1998) Dose-limiting neurotoxicity in a Phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic α-picoline derivative, administered intravenously. Br J Cancer 77: 808–811.

    CAS  Article  Google Scholar 

  22. Joint Steering Committee of the EORTC and CRC (1990). General guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. Eur J Cancer 26: 411–414

  23. Judson, IR, Calvert, AH, Rutty, CJ, Abel, G, Gumbrell, LA, Graham, MA, Evans, BD, Wilman, DEV, Ashley, SE & Cairnduff, F (1989) Phase I trial and pharmacokinetics of trimelamol (N2 N4 N6-trihydroxymethyl-N2 N4 N6-trimethylmelamine). Cancer Res 49: 5475–5479.

    CAS  PubMed  Google Scholar 

  24. Judson, I, Briasoulis, E, Raynaud, F, Hanwell, J, Berry, C & Lacey, H (1997) Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85, a synthetic agent binding at the colchicine site designed to overcome multidrug resistance. Br J Cancer 75: 608–613.

    CAS  Article  Google Scholar 

  25. Kerr, DJ, Kaye, SB, Graham, J, Cassidy, J, Harding, M, Setanoians, A, McGrath, JC, Vezin, WR, Cunningham, D, Forrest, G & Soukop, M (1986) Phase I and pharmacokinetic study of LM975 (flavone acetic acid ester). Cancer Res 46: 3142–3146.

    CAS  PubMed  Google Scholar 

  26. Kerr, DJ, Kaye, SB, Cassidy, J, Bradley, C, Rankin, EM, Adams, L, Setanoians, A, Young, T, Forrest, G, Soukop, M & Clavel, M (1987) Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res 47: 6776–6781.

    CAS  PubMed  Google Scholar 

  27. McKeage, MJ, Mistry, P, Ward, J, Boxall, FE, Loh, S, O’Neill, C, Ellis, P, Kelland, LR, Morgan, SE, Murrer, B, Santabarbara, P, Harrap, KR & Judson, IR (1995) A Phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 36: 451–458.

    CAS  Article  Google Scholar 

  28. McKeage, MJ, Raynaud, F, Ward, J, Berry, C, O’Dell, D, Kelland, LR, Murrer, B, Santabarbara, P, Harrap, KR & Judson, IR (1997) Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 15: 2691–2700.

    CAS  Article  Google Scholar 

  29. Mick, R & Ratain, MJ (1993) Model-guided determination of maximum tolerated dose in Phase I clinical trials: evidence for increased precision. J Natl Cancer Inst 85: 217–223.

    CAS  Article  Google Scholar 

  30. Millward, MJ, Newell, DR, Mummaneni, V, Igwemezie, LN, Balmanno, K, Charlton, CJ, Gumbrell, L, Lind, MJ, Chapman, F, Proctor, M, Simmonds, D, Cantwell, BMJ, Taylor, GA, McDaniel, C, Winograd, B, Kaul, S, Barbaiya, RH & Calvert, AH (1995) Phase I and pharmacokinetic study of the water-soluble etoposide prodrug, etoposide phosphate (BMY-40481). Eur J Cancer 31A: 2409–2411.

    CAS  Article  Google Scholar 

  31. Newlands, ES, Blackledge, G, Slack, JA, Goddard, C, Brindley, CJ, Holden, L & Stevens, MFG (1985) Phase I clinical trial of mitozolomide. Cancer Treat Rep 69: 801–805.

    CAS  PubMed  Google Scholar 

  32. Newlands, ES, Blackledge, GRP, Slack, JA, Rustin, GJS, Smith, DB, Stuart, NSA, Quarterman, CP, Hoffman, R, Stevens, MFG, Brampton, MH & Gibson, AC (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65: 287–291.

    CAS  Article  Google Scholar 

  33. Newlands, ES, Rustin, GJS & Brampton, MH (1996) Phase I trial of elactocin. Br J Cancer 74: 648–649.

    CAS  Article  Google Scholar 

  34. O’Quigley, J & Chevret, S (1991) Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Stat Med 10: 1647–1664.

    Article  Google Scholar 

  35. Penta, JS, Rozencweig, M, Guarino, AM & Muggia, FM (1979) Mouse and large-animal toxicology studies of twelve antitumour agents: relevance to starting dose for Phase I clinical trials. Cancer Chemother Pharmacol 3: 97–101.

    CAS  Article  Google Scholar 

  36. Penta, JS, Rosner, GL & Trump, DL (1992) Choice of starting dose and escalation for Phase I studies of antitumour agents. Cancer Chemother Pharmacol 31: 247–250.

    CAS  Article  Google Scholar 

  37. Phillip, PA, Rea, D, Thavasu, P, Carmichael, J, Stuart, NSA, Rockett, H, Talbot, DC, Ganesan, T, Pettit, GR, Balkwill, F & Harris, AL (1993) Phase I study of bryostatin 1: assessment of interleukin 6 and tumour necrosis factor α induction in vivo. J Natl Cancer Inst 85: 1812–1818.

    Article  Google Scholar 

  38. Prendiville, J, Crowther, D, Thatcher, N, Woll, PJ, Fox, BW, McGown, A, Testa, N, Stern, P, McDermott, R, Potter, M & Pettit, GR (1993) A Phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 68: 418–424.

    CAS  Article  Google Scholar 

  39. Rafi, I, Taylor, GA, Calvete, JA, Boddy, AV, Balmanno, K, Bailey, N, Lind, M, Calvert, AH, Webber, S, Jackson, RJ, Johnston, A, Clendeninn, N & Newell, DR (1995) Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazoline dihydrochloride (AG337) given by 24-hour intravenous infusion. Clin Cancer Res 1: 1275–1284.

    CAS  PubMed  Google Scholar 

  40. Rafi, I, Boddy, AV, Calvete, JA, Taylor, GA, Newell, DR, Bailey, NP, Lind, MJ, Green, M, Hine, J, Johnston, A, Clendeninn, N & Calvert, AH (1998) Preclinical and Phase I clinical studies with the non-classical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumours. J Clin Oncol 16: 1131–1141.

    CAS  Article  Google Scholar 

  41. Ratain, MJ, Mick, R, Schilsky, RL & Siegler, M (1993) Statistical and ethical issues in the design and conduct of Phase I and Phase II clinical trials of new anticancer agents. J Natl Cancer Inst 85: 1637–1643.

    CAS  Article  Google Scholar 

  42. Rozencweig, M, Von Hoff, DD, Staquet, MJ, Schein, PS, Penta, JS, Goldin, A, Muggia, FM, Freireich, EJ & DeVite, VT (1981) Animal toxicology for early clinical trials with anticancer agents. Cancer Clin Trials 4: 21–28.

    CAS  PubMed  Google Scholar 

  43. Simon, R, Freidlin, B, Rubinstein, L, Arbuck, S, Collins, J & Christian, MC (1997) Accelerated titration designs for Phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138–1147.

    CAS  Article  Google Scholar 

  44. Smith, DB, Fox, BW, Thatcher, N, Steward, WP, Scarffe, JH, Wagstaff, J, Vezin, R & Crowther, D (1987) Phase I clinical trial of methylene dimethyl sulfonate. Cancer Treat Rep 71: 817–820.

    CAS  PubMed  Google Scholar 

  45. Smith, DB, Ewen, C, Mackintosh, J, Fox, BW, Thatcher, N, Scarffe, JH, Vezin, R & Crowther, D (1988) A Phase I trial and pharmacokinetic study of amphethinile. Br J Cancer 57: 623–627.

    CAS  Article  Google Scholar 

  46. Stuart, NSA, Crawford, SM, Blackledge, GRP, Newlands, ES, Slack, J, Hoffman, R & Stevens, MFG (1989) A Phase I study of meta-azidopyrimethamine ethanesulphonate (MZPES): a new dihydrofolate reductase inhibitor. Cancer Chemother Pharmacol 23: 308–310.

    CAS  Article  Google Scholar 

  47. Vasey, PA, Kaye, SB, Morrison, R, Twelves, C, Wilson, P, Duncan, R, Thomson, AH, Murray, LS, Hilditch, TE, Murray, T, Burtles, S, Fraier, D, Frigerio, E & Cassidy, J (1999). Clin Cancer Res 5: 83–94.

  48. Veale, D, Carmichael, J, Cantwell, BMJ, Elford, HL, Blackie, R, Kerr, DJ, Kaye, SB & Harris, AL (1988) A Phase I and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor. Br J Cancer 58: 70–72.

    CAS  Article  Google Scholar 

  49. Verweij, J (1996) Starting dose levels for Phase I studies. Ann Oncol 7, (suppl.1) 13

    Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and Permissions

About this article

Cite this article

Newell, D., Burtles, S., Fox, B. et al. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Br J Cancer 81, 760–768 (1999). https://doi.org/10.1038/sj.bjc.6690761

Download citation

Keywords

  • phase I trials
  • preclinical toxicology
  • starting dose

Further reading

Search

Quick links